EXEL vs. CRSP

Last updated Apr 1, 2026

Compare and contrast key facts about Exelixis, Inc. (EXEL) and CRISPR Therapeutics AG (CRSP).

Performance

EXEL vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Exelixis, Inc. (EXEL) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

EXEL vs. CRSP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
EXEL Exelixis, Inc.	-2.14%	31.62%	38.81%	49.56%	-12.25%	-8.92%	13.90%	-10.42%	-35.30%	103.89%
CRSP CRISPR Therapeutics AG	-9.29%	33.23%	-37.12%	54.00%	-46.36%	-50.51%	151.39%	113.18%	21.68%	15.89%

Fundamentals

EPS EXEL : $2.76 CRSP : -$5.47
PS Ratio EXEL : 5.24 CRSP : 115.43
Total Revenue (TTM) EXEL : $2.32B CRSP : $36.75M
Gross Profit (TTM) EXEL : $2.24B CRSP : -$130.60M
EBITDA (TTM) EXEL : $934.65M CRSP : -$529.50M

Returns By Period

In the year-to-date period, EXEL achieves a -2.14% return, which is significantly higher than CRSP's -9.29% return.

EXEL

• 1D: 2.24%
• 1M: -2.66%
• YTD: -2.14%
• 6M: 3.85%
• 1Y: 16.17%
• 3Y*: 30.25%
• 5Y*: 13.15%
• 10Y*: 26.62%

CRSP

• 1D: 7.28%
• 1M: -20.90%
• YTD: -9.29%
• 6M: -26.60%
• 1Y: 39.79%
• 3Y*: 1.70%
• 5Y*: -16.81%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

EXEL vs. CRSP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EXEL

EXEL Risk / Return Rank: 56
EXEL Sharpe Ratio Rank: 56
EXEL Sortino Ratio Rank: 52
EXEL Omega Ratio Rank: 54
EXEL Calmar Ratio Rank: 58
EXEL Martin Ratio Rank: 58

CRSP

CRSP Risk / Return Rank: 61
CRSP Sharpe Ratio Rank: 65
CRSP Sortino Ratio Rank: 65
CRSP Omega Ratio Rank: 61
CRSP Calmar Ratio Rank: 58
CRSP Martin Ratio Rank: 56

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EXEL vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	EXEL	CRSP	Difference
Sharpe ratio Return per unit of total volatility	0.37	0.63	-0.26
Sortino ratio Return per unit of downside risk	0.83	1.36	-0.53
Omega ratio Gain probability vs. loss probability	1.12	1.16	-0.03
Calmar ratio Return relative to maximum drawdown	0.67	0.68	-0.01
Martin ratio Return relative to average drawdown	1.55	1.35	+0.21
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

EXEL vs. CRSP - Sharpe Ratio Comparison

The current EXEL Sharpe Ratio is 0.37, which is lower than the CRSP Sharpe Ratio of 0.63. The chart below compares the historical Sharpe Ratios of EXEL and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	EXEL	CRSP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.37	0.63	-0.26
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.36	-0.28	+0.64
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.60	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.07	0.21	-0.15

Correlation

The correlation between EXEL and CRSP is 0.33, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

EXEL vs. CRSP - Dividend Comparison

Neither EXEL nor CRSP has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

EXEL vs. CRSP - Drawdown Comparison

The maximum EXEL drawdown since its inception was -97.38%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for EXEL and CRSP.

Drawdown Indicators

	EXEL	CRSP	Difference
Max Drawdown Largest peak-to-trough decline	-97.38%	-85.11%	-12.27%
Max Drawdown (1Y) Largest decline over 1 year	-25.34%	-42.25%	+16.91%
Max Drawdown (5Y) Largest decline over 5 years	-41.47%	-80.68%	+39.21%
Max Drawdown (10Y) Largest decline over 10 years	-57.20%	—	—
Current Drawdown Current decline from peak	-12.91%	-77.35%	+64.44%
Average Drawdown Average peak-to-trough decline	-71.55%	-48.69%	-22.86%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.85%	21.22%	-10.37%

Volatility

EXEL vs. CRSP - Volatility Comparison

The current volatility for Exelixis, Inc. (EXEL) is 6.86%, while CRISPR Therapeutics AG (CRSP) has a volatility of 18.14%. This indicates that EXEL experiences smaller price fluctuations and is considered to be less risky than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	EXEL	CRSP	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.86%	18.14%	-11.28%
Volatility (6M) Calculated over the trailing 6-month period	26.58%	44.86%	-18.28%
Volatility (1Y) Calculated over the trailing 1-year period	43.76%	64.29%	-20.53%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	36.84%	60.36%	-23.52%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	44.88%	64.43%	-19.55%

Financials